Quarterly ResultMay 18, 2026, 08:39 AM
Scienture Holdings Q1 Revenue +449% to $56K; Gross Profit +7900%
AI Summary
Scienture Holdings reported strong financial results for Q1 2026, with revenue increasing 449% year-over-year to $56 thousand and gross profit soaring 7900% to $54 thousand, driven by incremental product orders for ArbliTM. The company also achieved significant operational milestones, including securing a third patent for ArbliTM and an Orange Book-listable patent for REZENOPYTM, alongside formalizing GPO agreements for REZENOPYTM to expand market access. Additionally, Scienture secured $11.0 million in non-dilutive debt financing to support growth and R&D, aiming for anticipated profitability in 2027.
Key Highlights
- Revenue increased 449% to $56 thousand for Q1 2026, up from $10 thousand in Q1 2025.
- Gross profit surged 7900% to $54 thousand in Q1 2026, from $673 in Q1 2025.
- Gross margin expanded to 95.6% in Q1 2026, compared to 6.6% in the prior-year period.
- Net loss was approximately $3.4 million for Q1 2026, compared to $3.1 million in Q1 2025.
- Secured $11.0 million in non-dilutive debt financing to accelerate growth.
- USPTO granted a third patent for ArbliTM, extending exclusivity through 2041.
- Received an Orange Book-listable patent for REZENOPYTM nasal spray 10 mg.
- Formalized multiple commercial GPO agreements for REZENOPYTM, expanding access to 60% of the U.S. institutional market.
Price Impact
More from SCNX